List All Graft-Versus-Host Disease Trials

Graft-Versus-Host Disease

 

Cyclophosphamide for Preventing Graft-Versus-Host Disease (FHCRC-2541)
A Phase II Study to Evaluate the Efficacy of Posttransplant Cyclophosphamide for Prevention of Chronic Graft-versus-Host Disease after Allogeneic Peripheral Blood Stem Cell Transplantation

Investigator: Marco Mielcarek, MD;   Conditions: Chronic Graft Versus Host Disease (cGVHD);    Status: Closed;   Study ID: NCT01427881

Imatinib Mesylate and Rituximab in Treating Cutaneous Sclerosis for Chronic GVHD (FHCRC-2343)
A Randomized Phase 2 Study of Imatinib and Rituximab for Cutaneous Sclerosis in Patients with Chronic Graft-Versus-Host Disease

Investigator: Mary Flowers, MD;   Conditions: Chronic Graft Versus Host Disease (cGVHD);    Status: Closed;   Study ID: NCT01309997

Alefacept for Steroid-Refractory Chronic GVHD (2469)
A Phase II, Open-Label, Multi-Center Study to Assess the Safety and Efficacy of Alefacept in Subjects with Steroid-Refractory Chronic Graft-versus-Host Disease

Investigator: Stephanie Lee, MD, MPH;   Conditions: Chronic Graft Versus Host Disease (cGVHD);    Status: Closed;   Study ID: NCT01226420

Tacrolimus + Mycophenolate Mofetil Post Transplant (FHCRC-1898)
A Multi-Center Study of Nonmyeloablative Conditioning with TBI or Fludarabine/TBI for HLA-matched Related Hematopoietic Cell Transplantation for Treatment of Hematologic Malignancies with Post Grafting Immunosuppression with Tacrolimus and Mycophenolate Mofetil

Investigator: David Maloney, MD, PhD;   Conditions: Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases;    Status: Closed;   Study ID: NCT00089011

Chronic Graft-versus-Host Disease Treatment (FHCRC-2375)
A Phase II/III Randomized, Multicenter Trial Comparing Sirolimus plus Prednisone, Sirolimus/Extracorporeal Photopheresis plus Prednisone, and Sirolimus/Calcineurin Inhibitor plus Prednisone for the Treatment of Chronic Graft-versus-Host Disease (BMT CTN 0801)

Investigator: Paul Carpenter, MD;   Conditions: Bone Marrow and Hematopoietic Stem Cell Transplant (BMT and HSCT);    Status: Closed;   Study ID: NCT01106833

Nilotinib in Steroid Dependent / Refractory Chronic GVHD (2423)
A Phase 1 Study of Nilotinib in Steroid Dependent / Refractory Chronic Graft Versus Host Disease

Investigator: Paul Carpenter, MD;   Conditions: Chronic Graft Versus Host Disease (cGVHD);    Status: Closed;   Study ID: NCT01155817

Sirolimus, Cyclosporine, and Mycophenolate Mofetil In Preventing GVHD for Undergoing Donor Peripheral Blood Stem Cell Transplant (FHCRC-2206)
A Phase II Study to Assess Immunosuppression with Sirolimus Combined with Cyclosporine (CSP) and Mycophenolate mofetil (MMF) for Prevention of Acute GVHD after Non-myeloablative HLA Class I or II Mismatched Donor Hematopoietic Cell Transplantation. A Multi-Center Trial

Investigator: Brenda Sandmaier, MD;   Conditions: Hematologic Malignancies;    Status: Recruiting;   Study ID: NCT01251575

Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant (FHCRC-2448)
A Randomized Phase II Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD after Unrelated Donor Hematopoietic Cell Transplantation using Nonmyeloablative Conditioning for Patients with Hematologic Malignancies: A Multi-Center Trial

Investigator: Brenda Sandmaier, MD;   Conditions: Hematologic Malignancies;    Status: Recruiting;   Study ID: NCT01231412

Depletion of T Cells From Allogeneic Stem Cell Grafts for the Prevention of GVHD (FHCRC-2222)
A Multi-center Phase II Study of Selective Depletion of CD45RA+ T cells from Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD

Investigator: Marie Bleakley, MD;   Conditions: Acute Lymphoid Leukemia (ALL);, Acute Myeloid Leukemia (AML), Hematologic Malignancies, Myelodysplastic Syndromes (MDS) Myeloproliferative Syndromes (MPD);    Status: Closed;   Study ID: NCT00914940

Sirolimus-Based Graft Versus Host Disease Prophylaxis Post Transplant (COG ASCT0431)
A Randomized Trial Of Sirolimus-Based Graft Versus Host Disease Prophylaxis After Hematopoietic Stem Cell Transplant

Investigator: Jean Sanders, MD;   Conditions: Graft Versus Host Disease, Leukemia;    Status: Closed;   Study ID: NCT00382109

Montelukast for Bronchiolitis Obliterans Post Transplant (2317)
Multi-Institutional Phase II Study of Montelukast for the Treatment of Bronchiolitis Obliterans Following Allogeneic Stem Cell Transplantation in Children and Adults

Investigator: Paul Martin, MD;   Conditions: Bronchiolitis Obliterans, Chronic Graft-versus-host Disease;    Status: Closed;   Study ID: NCT00656058

Targeted Therapy of Bronchiolitis Obliterans Syndrome (2367)
Fluticasone Propionate, Azithromycin, and Montelukast Sodium in Treating Patients With Bronchiolitis Obliterans Who Previously Underwent Stem Cell Transplant

Investigator: Paul Martin, MD;   Conditions: Chronic Graft Versus Host Disease (cGVHD);    Status: Closed;   Study ID: NCT01307462

Low-Dose Prednisone or Methylprednisolone for GVHD (FHCRC-2327)
A Phase III Study to Assess Efficacy and Safety of Low-Dose Glucocorticoids for Initial Treatment of Acute Graft-versus-Host Disease

Investigator: Marco Mielcarek, MD;   Conditions: Graft Versus Host Disease;    Status: Recruiting;   Study ID: NCT00929695

Alpha 1 Anti-Trypsin for Acute GVHD (2571)
Treatment of steroid non-responsive acute GVHD with alpha 1 anti-trypsin (AAT). A phase I/II study.

Investigator: Joachim Deeg, MD;   Conditions: Graft Versus Host Disease;    Status: Closed;   Study ID: NCT01523821

Brentuximab Vedotin for Steroid-Resistant Acute GVHD (FH 2589)
Phase II Study to Evaluate the Efficacy of Brentuximab Vedotin in Patients with Steroid-Resistant Acute GVHD

Investigator: Merav Bar, MD;   Conditions: Chronic Graft Versus Host Disease (cGVHD);    Status: Closed;   Study ID: NCT01616680

Abatacept + Calcineurin Inhibitor + Methotrexate for Graft Versus Host Disease (2692)
Abatacept Combined with a Calcineurin Inhibitor and Methotrexate for Graft Versus Host Disease Prophylaxis: A Randomized Controlled Trial

Investigator: Leslie S Kean, MD/PhD ;   Conditions: Graft vs Host Disease;    Status: Recruiting;   Study ID: NCT01743131

Chronic GVHD Response Measures Validation (2710)
Chronic GVHD Response Measures Validation

Investigator: Stephanie Lee, MD, MPH;   Conditions: Chronic Graft Versus Host Disease (cGVHD); Non-malignant Condition;    Status: Recruiting;   Study ID: NCT01902576

Selective Depletion of CD45RA+ T Cells From Allogeneic Stem Cell Grafts for Prevention of GVHD (2684)
A Phase II Study Evaluating Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors for Prevention of GVHD

Investigator: Marie E. Bleakley, MD;   Conditions: Leukemia;    Status: Pending;   Study ID: NCT02220985

Ibrutinib for Steroid Dependent or Refractory Chronic GVHD (9326)
A Multicenter Open-Label Phase 1b/2 Study of Ibrutinib in Steroid Dependent or Refractory Chronic Graft Versus Host Disease

Investigator: Mary Flowers, MD;   Conditions: Graft Versus Host Disease;    Status: Recruiting;   Study ID: NCT02195869

Carfilzomib for Chronic Graft-Versus-Host Disease (9228)
Carfilzomib for Treatment of Chronic Graft-Versus-Host Disease (GVHD)

Investigator: Stephanie Lee, MD, MPH;   Conditions: Graft Versus Host Disease, Chronic (cGVHD); Graft Versus Host Disease (GVHD);    Status: Recruiting;   Study ID: NCT02491359